SCHEMBL6234928

SCHEMBL6234928

COCCO[C@@H]1[C@H](OP(OCC[Si](C)(c2ccccc2)c2ccccc2)N(C(C)C)C(C)C)[C@@H](C(OC(c2ccccc2)(c2ccc(OC)cc2)c2ccc(OC)cc2)C(=O)c2ccccc2)O[C@H]1n1ccc(N)nc1=O

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ST6GAL1 P15907 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6234866 0.87 ST6GAL1 (0.32) ST6GAL1
SCHEMBL6238364 0.85 P2RX3 (0.37)
SCHEMBL7074034 0.85 ST6GAL1 (0.38) ST6GAL1
SCHEMBL6835020 0.83 ST6GAL1 (0.43) ST6GAL1
SCHEMBL2108247 0.80 ST6GAL1 (0.31) ST6GAL1
SCHEMBL6234136 0.79 TAAR1 (0.39)
SCHEMBL15841537 0.79 ST6GAL1 (0.31) ST6GAL1
SCHEMBL10693710 0.79 ST6GAL1 (0.38) ST6GAL1
SCHEMBL15643220 0.79
SCHEMBL5396749 0.77 POLB (0.31) ST6GAL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0948514-B1 METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES ISIS PHARMACEUTICALS INC (US) 2005-04-27 EP disclosed
US-20030013864-A1 Method for the synthesis of nucleotide of oligonucleotide phosphoramidites GRIFFEY RICHARD H (US) 2003-01-16 US disclosed
US-6458941-B1 RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS ISIS PHARMACEUTICALS, INC. 2002-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013864-A1 Method for the synthesis of nucleotide of oligonucleotide phosphoramidites NUDT1, MTAP, PHOSPHO1 ST6GAL1 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.